BiomX Inc. (NYSEAMERICAN:PHGE – Get Free Report) shares fell 1.3% on Wednesday . The company traded as low as $0.74 and last traded at $0.77. 40,241 shares traded hands during trading, a decline of 26% from the average session volume of 54,108 shares. The stock had previously closed at $0.78.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and issued a $2.00 price target on shares of BiomX in a report on Wednesday, January 8th.
Get Our Latest Research Report on PHGE
BiomX Trading Down 1.3 %
BiomX Company Profile
BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).
See Also
- Five stocks we like better than BiomX
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- What is the Australian Securities Exchange (ASX)
- 3 Steel Stocks Soaring After Tariff Announcements
- What is the S&P 500 and How It is Distinct from Other Indexes
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.